Recombinant interleukin-2 treatment in patients with metastatic colorectal cancer: Effect on natural cytotoxicity

@article{Park1992RecombinantIT,
  title={Recombinant interleukin-2 treatment in patients with metastatic colorectal cancer: Effect on natural cytotoxicity},
  author={Kenneth G. M. Park and Steven D. Heys and Jillian B. Murray and Paul D Hayes and Jamie Alan Ashby and Charles Franks and O. G. Eremin},
  journal={Cancer Immunology, Immunotherapy},
  year={1992},
  volume={35},
  pages={53-58}
}
SummaryNatural cytotoxicity (natural killer, NK, and lymphokine-activated killer, LAK, activity) was documented in 12 patients with metastatic colorectal cancer, both before and after a 5-day course of continuous therapy with intravenous recombinant interleukin-2 (rIL-2). Treatment induced a substantial increase in circulating CD56+ lymphocytes (pretreatment: 12.1±6.9%, mean ± SD; posttreatment: 39.2±6.9%. Maximal NK cell activity was induced by treatment with rIL-2 but only suboptimal… CONTINUE READING
BETA

Similar Papers

References

Publications referenced by this paper.
SHOWING 1-10 OF 30 REFERENCES

Effect of interleukin-2 treatment on human natural cytotoxicity

KGM Park, SD Heys, +5 authors O Eremin
  • Eur J Surg Oncol
  • 1992
VIEW 1 EXCERPT

What's new in surgical oncology: impact of immunology and tumour biology.

  • Journal of the Royal College of Surgeons of Edinburgh
  • 1990
VIEW 1 EXCERPT

In vitro modification of the immune response induced by therapy with recombinant interleukin-2

PA Paciucci, RG Konefal, +3 authors JF Holland
  • Proc Am Assoc Cancer Res
  • 1988
VIEW 1 EXCERPT